{"id":7752,"date":"2026-04-28T20:01:26","date_gmt":"2026-04-28T17:01:26","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=7752"},"modified":"2026-05-15T13:57:36","modified_gmt":"2026-05-15T10:57:36","slug":"faq-pbgene-dmd-gene-editing-therapy","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/faq-pbgene-dmd-gene-editing-therapy\/","title":{"rendered":"PBGENE-DMD Gen D\u00fczenleme Terapisi: Faydalar\u0131, Uygunluk Kriterleri ve S\u0131k\u00e7a Sorulan Sorular"},"content":{"rendered":"<p class=\"wp-block-paragraph\"><strong>PBGENE-DMD Gen D\u00fczenleme Terapisi, Precision BioSciences taraf\u0131ndan Duchenne kas distrofisi (DMD) i\u00e7in geli\u015ftirilen, ara\u015ft\u0131rma a\u015famas\u0131nda olan ve alan\u0131nda ilk olma \u00f6zelli\u011fine sahip bir tedavi y\u00f6ntemidir.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Geleneksel tedavilerin aksine, PBGENE-DMD, ARCUS gen d\u00fczenleme teknolojisiyle desteklenen bir gen kesme stratejisi kullan\u0131r. Distrofin genini kal\u0131c\u0131 olarak d\u00fczenlemek \u00fczere tasarlanm\u0131\u015f iki ARCUS n\u00fckleaz\u0131n\u0131 kodlayan tek bir adeno-ili\u015fkili vir\u00fcs (AAV) vekt\u00f6r\u00fc arac\u0131l\u0131\u011f\u0131yla uygulan\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu yakla\u015f\u0131m\u0131n amac\u0131 \u015funlard\u0131r:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Distrofin genindeki hatal\u0131 DNA b\u00f6l\u00fcmlerini ortadan kald\u0131rmak<\/li>\n\n\n\n<li><strong>V\u00fccudun neredeyse tam uzunlukta, i\u015flevsel bir distrofin proteini \u00fcretmesini sa\u011flamak<\/strong><\/li>\n\n\n\n<li>Uzun vadeli ve potansiyel olarak kal\u0131c\u0131 kas geli\u015fimi sa\u011flamak<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Klinik \u00f6ncesi veriler, PBGENE-DMD&#039;nin iskelet kas\u0131, diyafram ve kalp dokusu da dahil olmak \u00fczere birden fazla kas tipinde distrofin ekspresyonunu geri kazand\u0131rabildi\u011fini ve ayn\u0131 zamanda s\u00fcrekli fayda i\u00e7in kritik \u00f6neme sahip olan kas uydu k\u00f6k h\u00fccrelerini d\u00fczenleyebildi\u011fini g\u00f6stermektedir. .<\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>\u0130\u00e7indekiler<\/h2><nav><ul><li><a href=\"#why-is-pbgene-dmd-gene-editing-therapy-important\">PBGENE-DMD Gen D\u00fczenleme Terapisi Neden \u00d6nemli?<\/a><ul><li><a href=\"#permanent-gene-editing\">Kal\u0131c\u0131 Gen D\u00fczenleme<\/a><\/li><li><a href=\"#near-full-length-dystrophin-production\">Neredeyse Tam Uzunlukta Distrofin \u00dcretimi<\/a><\/li><li><a href=\"#targeting-muscle-stem-cells\">Kas K\u00f6k H\u00fccrelerini Hedefleme<\/a><\/li><li><a href=\"#multi-tissue-impact\">\u00c7oklu Doku Etkisi<\/a><\/li><li><a href=\"#regulatory-recognition\">D\u00fczenleyicilerin Tan\u0131mas\u0131<\/a><\/li><\/ul><\/li><li><a href=\"#who-can-receive-pbgene-dmd-gene-editing-therapy-eligibility-fa-qs\">PBGENE-DMD Gen D\u00fczenleme Terapisi Kimlere Uygulanabilir? (Uygunluk Kriterleri Hakk\u0131nda S\u0131k\u00e7a Sorulan Sorular)<\/a><ul><li><a href=\"#\u2705-eligible-patients\">\u2705 Uygun Hastalar<\/a><\/li><li><a href=\"#faq-question-1777392685572\">Hangi ekzon delesyonlar\u0131 PBGENE-DMD gen d\u00fczenleme terapisi i\u00e7in uygundur?<\/a><\/li><li><a href=\"#faq-question-1777392706521\">Hangi fiziksel yetenekler gereklidir?<\/a><\/li><li><a href=\"#faq-question-1777392815309\">A\u015f\u0131lar zorunlu mu?<\/a><\/li><li><a href=\"#faq-question-1777392838933\">Onay gerekli mi?<\/a><\/li><li><a href=\"#faq-question-1777392849177\">Uzun s\u00fcreli takip gerekli mi?<\/a><\/li><\/ul><\/li><li><a href=\"#who-is-not-eligible-for-pbgene-dmd-exclusion-fa-qs\">PBGENE-DMD Program\u0131na Kimler Kat\u0131lamaz? (Kat\u0131l\u0131m D\u0131\u015f\u0131 B\u0131rakma Hakk\u0131nda S\u0131k\u00e7a Sorulan Sorular)<\/a><ul><li><a href=\"#\u274c-ineligible-patients\">\u274c Uygun Olmayan Hastalar<\/a><\/li><li><a href=\"#faq-question-1777393251291\">Daha \u00f6nce gen terapisi g\u00f6rm\u00fc\u015f hastalar kat\u0131labilir mi?<\/a><\/li><li><a href=\"#faq-question-1777393281660\">Peki ya ekzon atlama veya distrofin tedavileri?<\/a><\/li><li><a href=\"#faq-question-1777393309651\">Di\u011fer klinik ara\u015ft\u0131rmalara kat\u0131lan hastalar da uygun mu?<\/a><\/li><li><a href=\"#faq-question-1777393318621\">AAV antikoru pozitif olan hastalar uygun mu?<\/a><\/li><li><a href=\"#faq-question-1777393328468\">T\u00fcm DMD mutasyonlar\u0131 de\u011ferlendirmeye al\u0131nabilir mi?<\/a><\/li><li><a href=\"#faq-question-1777393410826\">Hangi kalp rahats\u0131zl\u0131klar\u0131 hastalar\u0131n d\u0131\u015flanmas\u0131na neden olur?<\/a><\/li><li><a href=\"#faq-question-1777393452605\">Ba\u011f\u0131\u015f\u0131kl\u0131k sistemini bask\u0131layan ila\u00e7lar\u0131n kullan\u0131m\u0131na ili\u015fkin kontrendikasyonlar\u0131 olan hastalar kat\u0131labilir mi?<\/a><\/li><\/ul><\/li><li><a href=\"#pbgene-dmd-gene-editing-therapy-fa-qs-from-families\">PBGENE-DMD Gen D\u00fczenleme Terapisi: Ailelerden S\u0131k\u00e7a Sorulan Sorular<\/a><ul><li><a href=\"#faq-question-1777394327672\">Elevidys ile tedavi edilen bir \u00e7ocuk ayn\u0131 zamanda PBGENE-DMD gen d\u00fczenleme terapisi de alabilir mi?<\/a><\/li><li><a href=\"#faq-question-1777394381372\">O\u011flumda DMD geninde 43. ekzon delesyonu mevcut ve PBGENE-DMD gen d\u00fczenleme tedavisi uygulanabilir mi?<\/a><\/li><li><a href=\"#faq-question-1777394586338\">Ekzon 48-55'te delesyon bulunan o\u011flum PBGENE-DMD gen d\u00fczenleme tedavisi alabilir mi?<\/a><\/li><li><a href=\"#faq-question-1777395554562\">PBGENE-DMD, ekzon 45 delesyonu olan DMD'li erkek \u00e7ocuklar i\u00e7in bir tedavi se\u00e7ene\u011fi midir?<\/a><\/li><\/ul><\/li><li><a href=\"#precision-bio-sciences-presents-new-preclinical-data-supporting-the-advancement-of-pbgene-dmd-into-clinic\">Precision BioSciences, PBGENE-DMD&#039;nin Klinik A\u015famaya Ge\u00e7i\u015fini Destekleyen Yeni Klinik \u00d6ncesi Veriler Sunuyor<\/a><\/li><li><a href=\"#final-thoughts\">Son D\u00fc\u015f\u00fcnceler<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"why-is-pbgene-dmd-gene-editing-therapy-important\"><strong>PBGENE-DMD Gen D\u00fczenleme Terapisi Neden \u00d6nemli?<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">PBGENE-DMD, Duchenne kas distrofisi tedavi stratejisinde \u00f6nemli bir de\u011fi\u015fimi temsil ediyor ve mevcut tedavilere g\u00f6re \u00e7e\u015fitli potansiyel avantajlar sunuyor:<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"permanent-gene-editing\"><strong>Kal\u0131c\u0131 Gen D\u00fczenleme<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Ekzon atlama gibi mevcut tedavilerin \u00e7o\u011fu, tekrarlanan dozlama gerektirir ve ge\u00e7ici etkiler sa\u011flar. PBGENE-DMD ise DNA'y\u0131 kal\u0131c\u0131 olarak de\u011fi\u015ftirmeyi hedefleyerek potansiyel olarak tek seferlik bir tedavi yakla\u015f\u0131m\u0131 sunabilir.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"near-full-length-dystrophin-production\"><strong>Neredeyse Tam Uzunlukta Distrofin \u00dcretimi<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">K\u0131salt\u0131lm\u0131\u015f proteinler \u00fcreten mikrodistrofin terapilerinin aksine, PBGENE-DMD daha eksiksiz ve i\u015flevsel bir distrofin proteinini geri kazand\u0131rmak \u00fczere tasarlanm\u0131\u015ft\u0131r ve bu da klinik sonu\u00e7lar\u0131 iyile\u015ftirebilir.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"targeting-muscle-stem-cells\"><strong>Kas K\u00f6k H\u00fccrelerini Hedefleme<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">PBGENE-DMD, uydu h\u00fccrelerini d\u00fczenleyerek, di\u011fer tedavilerin \u00f6nemli bir s\u0131n\u0131rlamas\u0131 olan kas yenilenmesini ve uzun vadeli dayan\u0131kl\u0131l\u0131\u011f\u0131 destekleyebilir.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"multi-tissue-impact\"><strong>\u00c7oklu Doku Etkisi<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Klinik \u00f6ncesi \u00e7al\u0131\u015fmalar \u015fu alanlarda etkiler g\u00f6stermi\u015ftir:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>\u0130skelet kas\u0131<\/li>\n\n\n\n<li>Kalp kas\u0131<\/li>\n\n\n\n<li>Diyafram<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Bu durum, \u00f6zellikle DMD&#039;nin ilerlemesinde kalp ve solunum yetmezli\u011finin rol\u00fc g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda son derece \u00f6nemlidir.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"regulatory-recognition\"><strong>D\u00fczenleyicilerin Tan\u0131mas\u0131<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">PBGENE-DMD, FDA&#039;den a\u015fa\u011f\u0131dakiler de dahil olmak \u00fczere \u00f6nemli tan\u0131mlamalar alm\u0131\u015ft\u0131r:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>H\u0131zl\u0131 Yol atamas\u0131<\/li>\n\n\n\n<li>Yetim \u0130la\u00e7 stat\u00fcs\u00fc<\/li>\n\n\n\n<li>Nadir Pediatrik Hastal\u0131k tan\u0131m\u0131<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"who-can-receive-pbgene-dmd-gene-editing-therapy-eligibility-fa-qs\"><strong>PBGENE-DMD Gen D\u00fczenleme Terapisi Kimlere Uygulanabilir? (Uygunluk Kriterleri Hakk\u0131nda S\u0131k\u00e7a Sorulan Sorular)<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">A\u015fa\u011f\u0131daki kriterler, klinik ara\u015ft\u0131rmalara kat\u0131l\u0131m \u015fartlar\u0131na dayanmaktad\u0131r.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"\u2705-eligible-patients\">\u2705 <strong>Uygun Hastalar<\/strong><\/h3>\n\n\n<div id=\"rank-math-faq\" class=\"rank-math-block\">\n<div class=\"rank-math-list\">\n<div id=\"faq-question-1777392685572\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\"><strong>Hangi ekzon delesyonlar\u0131 PBGENE-DMD gen d\u00fczenleme terapisi i\u00e7in uygundur?<\/strong><\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Hastalar\u0131n, 45-55. ekzonlar aras\u0131nda tamamen yer alan, do\u011frulanm\u0131\u015f bir DMD mutasyonuna sahip olmalar\u0131 gerekmektedir.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1777392706521\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\"><strong>Hangi fiziksel yetenekler gereklidir?<\/strong><\/h3>\n<div class=\"rank-math-answer\">\n\n<p>2 ila &lt;4 ya\u015f aras\u0131:<\/p>\n<p>\u2022 En az 10 metreyi ba\u011f\u0131ms\u0131z olarak y\u00fcr\u00fcyebilme yetene\u011fi<br \/>\u2022 Yerden kalkabilme yetene\u011fi <a href=\"https:\/\/dmdwarrior.com\/tr\/gowers-sign-in-duchenne-muscular-dystrophy\/\" data-type=\"post\" data-id=\"7263\">(Gowers'\u0131n manevras\u0131 ile kalkanlar da uygundur)<\/a><\/p>\n<p>4 ila 7 ya\u015f aras\u0131:<\/p>\n<p>\u2022 En az 100 metreyi ba\u011f\u0131ms\u0131z olarak y\u00fcr\u00fcyebilme yetene\u011fi<br \/>\u2022 NSAA puan\u0131 16 ile 29 aras\u0131nda<\/p>\n<p>Daha fazla bilgi edin: <a href=\"https:\/\/dmdwarrior.com\/tr\/north-star-ambulatory-assessment-nsaa-in-duchenne-dmd\/\" target=\"_blank\" data-type=\"post\" data-id=\"4959\" rel=\"noreferrer noopener\">NSAA<\/a><\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1777392815309\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\"><strong>A\u015f\u0131lar zorunlu mu?<\/strong><\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Evet. Hastalar\u0131n rutin \u00e7ocukluk \u00e7a\u011f\u0131 a\u015f\u0131lar\u0131n\u0131n g\u00fcncel olmas\u0131 gerekmektedir.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1777392838933\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\"><strong>Onay gerekli mi?<\/strong><\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Evet. Ebeveynler veya yasal vasiler yaz\u0131l\u0131 bilgilendirilmi\u015f onam vermelidir ve \u00e7ocuklar da uygun durumlarda r\u0131za g\u00f6stermelidir.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1777392849177\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\"><strong>Uzun s\u00fcreli takip gerekli mi?<\/strong><\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Evet. Hastalar\u0131n uzun s\u00fcreli takip (LTFU) \u00e7al\u0131\u015fmas\u0131na kat\u0131lmay\u0131 kabul etmeleri gerekmektedir.<\/p>\n\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"who-is-not-eligible-for-pbgene-dmd-exclusion-fa-qs\"><strong>PBGENE-DMD Program\u0131na Kimler Kat\u0131lamaz? (Kat\u0131l\u0131m D\u0131\u015f\u0131 B\u0131rakma Hakk\u0131nda S\u0131k\u00e7a Sorulan Sorular)<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"\u274c-ineligible-patients\">\u274c <strong>Uygun Olmayan Hastalar<\/strong><\/h3>\n\n\n<div id=\"rank-math-faq\" class=\"rank-math-block\">\n<div class=\"rank-math-list\">\n<div id=\"faq-question-1777393251291\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\"><strong>Daha \u00f6nce gen terapisi g\u00f6rm\u00fc\u015f hastalar kat\u0131labilir mi?<\/strong><\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Hay\u0131r. \u015eu konularda herhangi bir ge\u00e7mi\u015finiz var m\u0131:<\/p>\n<p>\u2022 Gen terapisi<br \/>\u2022 Gen d\u00fczenleme<br \/>\u2022 H\u00fccre bazl\u0131 tedavi<br \/>\u2192 d\u0131\u015flanmayla sonu\u00e7lan\u0131r.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1777393281660\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\"><strong>Peki ya ekzon atlama veya distrofin tedavileri?<\/strong><\/h3>\n<div class=\"rank-math-answer\">\n\n<p>A\u015fa\u011f\u0131daki durumlarda hastalar \u00e7al\u0131\u015fmadan \u00e7\u0131kar\u0131l\u0131r:<\/p>\n<p>\u2022 Son 6 ay i\u00e7inde bu t\u00fcr tedavilerden yararlanm\u0131\u015f olmak<br \/>\u2022 Tedaviden sonra en az 5 y\u0131l boyunca bunlar\u0131 b\u0131rakmaya istekli olmamak<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1777393309651\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\"><strong>Di\u011fer klinik ara\u015ft\u0131rmalara kat\u0131lan hastalar da uygun mu?<\/strong><\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Hay\u0131r, ancak \u00e7al\u0131\u015fma g\u00f6zlemsel (m\u00fcdahale gerektirmeyen) bir \u00e7al\u0131\u015fma ise durum farkl\u0131 olabilir.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1777393318621\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\"><strong>AAV antikoru pozitif olan hastalar uygun mu?<\/strong><\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Hay\u0131r. Pozitif AAV9 antikor testi, kat\u0131l\u0131m\u0131 engeller.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1777393328468\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\"><strong>T\u00fcm DMD mutasyonlar\u0131 de\u011ferlendirmeye al\u0131nabilir mi?<\/strong><\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Ekzon 1-44 ve\/veya ekzon 56-79'da patojenik mutasyonlar\u0131 olan kat\u0131l\u0131mc\u0131lar.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1777393410826\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\"><strong>Hangi kalp rahats\u0131zl\u0131klar\u0131 hastalar\u0131n d\u0131\u015flanmas\u0131na neden olur?<\/strong><\/h3>\n<div class=\"rank-math-answer\">\n\n<p>A\u015fa\u011f\u0131daki rahats\u0131zl\u0131klara sahip hastalar:<\/p>\n<p>\u2022 <strong>Sol ventrik\u00fcl ejeksiyon fraksiyonu (LVEF) &lt; % 50<\/strong><br \/>\u2022 Kardiyomiyopati belirtileri d\u0131\u015flanm\u0131\u015ft\u0131r.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1777393452605\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\"><strong>Ba\u011f\u0131\u015f\u0131kl\u0131k sistemini bask\u0131layan ila\u00e7lar\u0131n kullan\u0131m\u0131na ili\u015fkin kontrendikasyonlar\u0131 olan hastalar kat\u0131labilir mi?<\/strong><\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Hay\u0131r. Gen terapisi ba\u011f\u0131\u015f\u0131kl\u0131k sistemini bask\u0131lamay\u0131 gerektirdi\u011finden, bu t\u00fcr hastalar uygun de\u011fildir.<\/p>\n\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"pbgene-dmd-gene-editing-therapy-fa-qs-from-families\">PBGENE-DMD Gen D\u00fczenleme Terapisi: Ailelerden S\u0131k\u00e7a Sorulan Sorular<\/h2>\n\n\n<div id=\"rank-math-faq\" class=\"rank-math-block\">\n<div class=\"rank-math-list\">\n<div id=\"faq-question-1777394327672\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\"><strong>Elevidys ile tedavi edilen bir \u00e7ocuk ayn\u0131 zamanda PBGENE-DMD gen d\u00fczenleme terapisi de alabilir mi?<\/strong><\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Hay\u0131r. Daha \u00f6nce Elevidys gibi gen terapisi alm\u0131\u015f hastalar, daha \u00f6nce gen terapisi alm\u0131\u015f olmak bir d\u0131\u015flama kriteri oldu\u011fu i\u00e7in PBGENE-DMD i\u00e7in uygun de\u011fildir. Ayr\u0131ca, AAV vekt\u00f6rlerine kar\u015f\u0131 ba\u011f\u0131\u015f\u0131kl\u0131k tepkileri g\u00fcvenli\u011fi ve etkinli\u011fi azaltabilir ve mevcut klinik protokollerde tekrarlayan gen tabanl\u0131 tedavilerden genellikle ka\u00e7\u0131n\u0131l\u0131r.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1777394381372\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\"><strong>O\u011flumda DMD geninde 43. ekzon delesyonu mevcut ve PBGENE-DMD gen d\u00fczenleme tedavisi uygulanabilir mi?<\/strong><\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Hay\u0131r. PBGENE-DMD, tamamen 45-55. ekzonlar i\u00e7inde yer alan mutasyonlar i\u00e7in tasarlanm\u0131\u015ft\u0131r. 43. ekzon silinmesi bu hedef aral\u0131\u011f\u0131n d\u0131\u015f\u0131nda kald\u0131\u011f\u0131 i\u00e7in mevcut uygunluk kriterlerini kar\u015f\u0131lamamaktad\u0131r.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1777394586338\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\"><strong>Ekzon 48-55'te delesyon bulunan o\u011flum PBGENE-DMD gen d\u00fczenleme tedavisi alabilir mi?<\/strong><\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Teknik olarak, bu delesyon hedef ekzon 45-55 aral\u0131\u011f\u0131na d\u00fc\u015ft\u00fc\u011f\u00fc i\u00e7in uygun olabilir. Bununla birlikte, ekzon 48-55 delesyonlar\u0131 genellikle daha hafif seyreden Becker kas distrofisi ile daha s\u0131k ili\u015fkilidir. Bu nedenle, bu alt grupta ara\u015ft\u0131rmay\u0131 geni\u015fletmek ve klinik sonu\u00e7lar\u0131 yay\u0131nlamak i\u00e7in Precision BioSciences&#039;yi beklemek ihtiyatl\u0131 olacakt\u0131r. BMD&#039;nin daha yava\u015f ilerlemesi g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda, dikkatli izleme ve sab\u0131r \u00f6nerilir.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1777395554562\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\"><strong>PBGENE-DMD, ekzon 45 delesyonu olan DMD'li erkek \u00e7ocuklar i\u00e7in bir tedavi se\u00e7ene\u011fi midir?<\/strong><\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Evet. PBGENE-DMD, mutasyonlar\u0131 tamamen 45-55. ekzonlar aras\u0131nda yer alan hastalar i\u00e7in tasarlanm\u0131\u015ft\u0131r ve 45. ekzon delesyonu bu hedef aral\u0131\u011f\u0131na girer. Bu nedenle, bu mutasyona sahip erkek \u00e7ocuklar, ya\u015f, fonksiyonel durum ve genel sa\u011fl\u0131k gereksinimleri gibi di\u011fer klinik kriterleri de kar\u015f\u0131lamalar\u0131 ko\u015fuluyla uygun olabilirler.<\/p>\n\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n<p class=\"wp-block-paragraph\">Daha fazla bilgi edin: <a href=\"https:\/\/precisionbiosciences.com\/arcus-genome-editing\/\" target=\"_blank\" rel=\"noreferrer noopener\">ARCUS Genom D\u00fczenleme<\/a><\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"precision-bio-sciences-presents-new-preclinical-data-supporting-the-advancement-of-pbgene-dmd-into-clinic\">Precision BioSciences, PBGENE-DMD&#039;nin Klinik A\u015famaya Ge\u00e7i\u015fini Destekleyen Yeni Klinik \u00d6ncesi Veriler Sunuyor<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Precision BioSciences, Amerikan Gen ve H\u00fccre Tedavisi Derne\u011fi&#039;nin (ASGCT) 2026 Y\u0131ll\u0131k Toplant\u0131s\u0131&#039;nda yapt\u0131\u011f\u0131 s\u00f6zl\u00fc sunumda, PBGENE-DMD program\u0131ndan elde edilen yeni preklinik verileri a\u00e7\u0131klad\u0131.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Erken d\u00f6nem ergenlik \u00e7a\u011f\u0131ndaki farelerde PBGENE-DMD, e\u015fde\u011fer doz seviyelerinde ge\u00e7 d\u00f6nem ergenlik \u00e7a\u011f\u0131ndaki farelere k\u0131yasla iskelet kas\u0131nda 3 kata kadar, solunum kas\u0131nda ise 12 kata kadar daha y\u00fcksek distrofin protein restorasyonu sa\u011flam\u0131\u015ft\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Solunum kas\u0131 dokular\u0131nda, beklenen distrofin protein restorasyonu terap\u00f6tik e\u015fi\u011fi olan % 5&#039;i a\u015fan g\u00fc\u00e7l\u00fc bir etkinlik g\u00f6zlemlendi; farelerde diyaframda % 12&#039;ye kadar ve interkostal kaslarda % 30&#039;a kadar distrofin restorasyonu sa\u011fland\u0131. Bu kaslar\u0131n i\u015flevi, DMD&#039;li hastalarda solunum yetmezli\u011fini \u00f6nlemede kritik \u00f6neme sahiptir.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u0130nsanla\u015ft\u0131r\u0131lm\u0131\u015f DMD fare modelinde yap\u0131lan bir toksikoloji \u00e7al\u0131\u015fmas\u0131, PBGENE-DMD tedavisinin, birden fazla doz seviyesinde serum kreatin kinaz\u0131nda 45%&#039;den daha fazla azalmaya yol a\u00e7t\u0131\u011f\u0131n\u0131 ve ara\u00e7la tedavi edilen kontrollere k\u0131yasla kas patolojisinde iyile\u015fmeler sa\u011flad\u0131\u011f\u0131n\u0131 g\u00f6stererek program\u0131n g\u00fcvenlik profilini desteklemi\u015ftir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>PBGENE-DMD, erken d\u00f6nem ergenlik \u00e7a\u011f\u0131ndaki farelerde y\u00fcksek d\u00fczeyde distrofin pozitif lif olu\u015fumuna yol a\u00e7t\u0131; \u00fc\u00e7 ay sonra iskelet ve solunum kas\u0131 dokular\u0131ndaki seviyeler, ge\u00e7 d\u00f6nem ergenlik \u00e7a\u011f\u0131ndaki farelere g\u00f6re 2-3 kat daha y\u00fcksek olup, distrofin pozitif liflerin oran\u0131 &#039;e kadar ula\u015ft\u0131.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Hem erken hem de ge\u00e7 d\u00f6nem ergenlik \u00e7a\u011f\u0131ndaki farelerin kalp kas\u0131nda benzer tedavi etkinli\u011fi elde edildi.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>G\u00fcvenli\u011fin \u00f6tesinde, PBGENE-DMD, distrofin protein restorasyonu ve distrofin pozitif miyofiberler yoluyla zaman i\u00e7inde s\u00fcrd\u00fcr\u00fclebilir etkinlik g\u00f6stermi\u015f ve bu da kal\u0131c\u0131 kas fonksiyonuna d\u00f6n\u00fc\u015fm\u00fc\u015ft\u00fcr.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Tedavi edilen fareler, sa\u011fl\u0131kl\u0131 hayvanlar\u0131n maksimum kuvvet \u00fcretiminin &#039;y\u00fczde 92&#039;sine kadar\u0131n\u0131 korurken, tedavi edilmeyen hasta farelerde kuvvet \u00fcretiminde giderek azalma g\u00f6r\u00fcld\u00fc.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"final-thoughts\">Son D\u00fc\u015f\u00fcnceler<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">PBGENE-DMD gen d\u00fczenleme terapisi, Duchenne kas distrofisinde kal\u0131c\u0131 genetik d\u00fczeltmeye do\u011fru bir ge\u00e7i\u015fi i\u015faret ediyor. K\u00f6k nedeni hedefleyerek, neredeyse tam uzunlukta distrofin restorasyonunu m\u00fcmk\u00fcn k\u0131labilir. Tek seferlik yakla\u015f\u0131m\u0131, tekrarlanan doz terapilerinden daha iyi sonu\u00e7lar verebilir. Bununla birlikte, kat\u0131 uygunluk kriterleri eri\u015fimi s\u0131n\u0131rlamaktad\u0131r. G\u00fcvenlik, kal\u0131c\u0131l\u0131k ve ger\u00e7ek d\u00fcnya sonu\u00e7lar\u0131 hala ara\u015ft\u0131rma a\u015famas\u0131ndad\u0131r. Devam eden \u00e7al\u0131\u015fmalar, uzun vadeli klinik etkisini belirleyecektir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Bu Sayfay\u0131 Takip Edin<\/strong>&nbsp;&gt;&gt;&gt;&nbsp;<a href=\"https:\/\/dmdwarrior.com\/tr\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Duchenne i\u00e7in T\u00fcm Klinik Ara\u015ft\u0131rmalar<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>PBGENE-DMD Gene Editing Therapy is an investigational, first-in-class treatment developed by Precision BioSciences for Duchenne muscular dystrophy (DMD). Unlike traditional therapies, PBGENE-DMD uses a gene excision strategy powered by ARCUS gene editing technology. It is delivered via a single adeno-associated virus (AAV) vector that encodes two ARCUS nucleases designed to permanently edit the dystrophin gene. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":7753,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[282],"tags":[726,359,725,314,724],"class_list":["post-7752","post","type-post","status-publish","format-standard","has-post-thumbnail","category-editorials","tag-arcus-gene-editing","tag-full-length-dystrophin","tag-gene-editing-therapy","tag-pbgene-dmd","tag-pbgene-dmd-therapy"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/7752","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=7752"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/7752\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/7753"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=7752"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=7752"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=7752"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}